Literature DB >> 3440105

Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules.

H A Tuynman1, H P Festen, K Röhss, S G Meuwissen.   

Abstract

Twelve male volunteers were studied after a single oral dose of 20 mg omeprazole given as enteric-coated granules with and without concomitant administration of 10 ml of a potent liquid antacid (buffering capacity 56.6 mmol 10 ml-1) under fasting conditions. No statistically significant differences were detected in median Cmax (0.41 approximately equal to 0.53 mumol l-1), the geometric mean AUC (0.80 approximately equal to 0.81 mumol l-1 h) or median tmax (1.25 h), with and without antacid.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3440105      PMCID: PMC1386414          DOI: 10.1111/j.1365-2125.1987.tb03256.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man.

Authors:  C W Howden; J A Forrest; J L Reid
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

2.  Oral pharmacokinetics of omeprazole.

Authors:  C W Howden; P A Meredith; J A Forrest; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

4.  Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.

Authors:  P O Lagerström; B A Persson
Journal:  J Chromatogr       Date:  1984-08-10

5.  Development of an oral formulation of omeprazole.

Authors:  A Pilbrant; C Cederberg
Journal:  Scand J Gastroenterol Suppl       Date:  1985

6.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Authors:  T Lind; C Cederberg; G Ekenved; U Haglund; L Olbe
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

7.  Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage.

Authors:  P J Prichard; N D Yeomans; G W Mihaly; D B Jones; P J Buckle; R A Smallwood; W J Louis
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

  7 in total
  8 in total

1.  Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.

Authors:  M S Ching; G W Mihaly; P W Angus; D J Morgan; S Devenish-Meares; N D Yeomans; R A Smallwood
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Influence of acid secretory status on absorption of omeprazole from enteric coated granules.

Authors:  T Andersson; R Bergstrand; C Cederberg
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

3.  The effect of antacids and metoclopramide on omeprazole absorption and disposition.

Authors:  C W Howden; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

Review 4.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 5.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 6.  Drug interactions with proton pump inhibitors.

Authors:  P Unge; T Andersson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 7.  Clinical pharmacology of omeprazole.

Authors:  C W Howden
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 8.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.